We found that TPL not only inactivated CAFs and reversed CAFs-induced tumor cell progression, but also sensitized GC cells to chemotherapy through attenuated NF-κB activation, suggesting its potential role in antitumor and reshaping TME via targeting CAFs in GC. The gene discussed is NFKB1; the disease is neoplasm.